TRex Bio

Private

#Immunology #Autoimmune #Inflammation #Dermatology

Clinical-stage immunoregulatory therapeutics company built on tissue regulatory T cell biology, combining high-resolution human tissue sequencing, computational biology and translational assay systems in its Deep Biology platform.

Company Info

Sector:Biotechnology / Immunology

Headquarters:South San Francisco, California, USA

Founded:2018

Website:trex.bio/

Clinical Development Pipeline

TRB-061

Target: TNFR2 agonist

Moderate-to-severe atopic dermatitis

Preclinical

Phase 1

Phase 2

Phase 3

Approved

TRB-031 / TRB-041 / TRB-051

Target: Tissue Treg modulation (partnered with Eli Lilly)

Inflammatory and autoimmune disease

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Johnston Erwin

Chief Executive Officer

Laura Berner

Chief Operating Officer

Careers & Job Openings

See all open roles

Careers

South San Francisco, California, USA

Apply Now →